NAPNN Conference

Saturday, May 16, 2026, 8:00 AM - 12:00 PM ET, Northern Michigan University - Peninsula Room #1, Northern Center, 1401 Presque Isle Avenue, Marquette , MI


AMA PRA Category 1 Credits™ (3.50 hours), Controlled Substance Prescribing (3.50 hours), DEA MATE Act (3.50 hours), Non-Physician Attendance (3.50 hours), Pain and Symptom Management (3.50 hours)

This continuing education activity is designed to enhance providers’ knowledge and practical skills in the management of opioid use disorder (OUD) within an interdisciplinary team, with a focus on buprenorphine prescribing in primary care and harm reduction strategies. The first session will begin with an overview of the evidence base for buprenorphine, including its mechanism of action, clinical effectiveness, and common myths and misconceptions. The second session will provide in-depth, practice-oriented guidance on prescribing buprenorphine in primary care settings. Content will include diagnostic criteria for OUD, use of the Clinical Opiate Withdrawal Scale (COWS), available formulations, initiation and maintenance strategies, and approaches to addressing common barriers in clinical practice. Case-based learning, including a nurse practitioner–focused case, will be integrated throughout to support application to real-world settings. The third session will focus on overdose prevention and response, including recognition of opioid overdose, naloxone administration, and core principles of harm reduction. The activity will conclude with facilitated discussion, expanded case review, and question-and-answer time to reinforce learning objectives and support participant engagement

1. Describe what buprenorphine is and explain its mechanism of action and clinical efficacy in the treatment of opioid use disorder.
2. Explain how buprenorphine supports long-term recovery and improves patient outcomes.
3. Discuss and advocate for evidence-based treatment of opioid use disorder within an interprofessional team.
4. Identify strategies to advocate for patients who use drugs or are experiencing addiction, regardless of professional role.
5. Apply harm reduction and overdose prevention principles in clinical practice.
6. Recognize and reflect on internalized stigma related to substance use and incorporate approaches to reduce stigma in patient care.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Michigan Medical School, University of Michigan School of Nursing, Northern Michigan University’s School of Nursing, and Michigan Council of Nurse Practitioner's local NAPNN Chapter. The University of Michigan Medical School is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
AMA PRA Category 1 
The University of Michigan Medical School designates this Live Activity for a maximum of 3.50 AMA PRA Category 1 Credit(s)™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Accessibility Statement
 
The University of Michigan Medical School is committed to ensuring that its programs, services, goods and facilities are accessible to individuals with disabilities as specified under Section 504 of the Rehabilitation Act of 1973 and the Americans with Disabilities Amendments Act of 2008.  If you have needs that require special accommodations, including dietary concerns, please contact the CME Activity Coordinator.

Questions? Please contact Casey Cummings or Katie Grandinetti.

Mitigation of Relevant Financial Relationships

The University of Michigan Medical School adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners, or others are required to disclose all relevant financial relationships with ineligible entities. All relevant financial relationships have been mitigated prior to the commencement of the activity.

Saturday, May 16, 2026